Impax Laboratories Inc. (IPXL) announced after the bell Monday that the FDA completed its re-inspection of the company's Hayward manufacturing facility in connection with the Form 483 issued in March last year. At the conclusion of the inspection, the FDA issued a new Form 483 with twelve observations, three of which are designated as repeat observations from inspections that occurred prior to the warning letter.
Impax Laboratories has gapped open dramatically lower Tuesday and is now down 4.87 at $15.13 on strong volume. The stock has plummeted to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.